Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Venetoclax for AML

Daniel Pollyea • 3 Sep 2020
SOHO 2020
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Azacitidine Cytarabine Venetoclax

Daniel Pollyea, MD, MS, of the University of Colorado, Denver, CO, outlines the use of venetoclax, a BCL-2 inhibitor, in acute myeloid leukemia (AML) and caveats associated with its use, including moving this treatment beyond its approved indication in unfit, relapsed/refractory AML. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Daniel Pollyea

1:08
The importance of predicting venetoclax response in patients with AML
Daniel Pollyea • 7 Sep 2023
1:11
Varied outcomes in patients with AML harboring poor-risk cytogenetics with or without TP53 mutation
Daniel Pollyea • 7 Sep 2023
1:00
The potential use of multi-gene molecular MRD testing in AML
Daniel Pollyea • 7 Sep 2023
1:13
Addressing whether AML with monocytic features should be considered a distinct clinical entity
Daniel Pollyea • 7 Sep 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals